公开(公告)号：US20230192752A1

公开(公告)日：2023-06-22

申请号：US16609367

申请日：2018-11-30

Applicant: Aptabio Therapeutics Inc. ,  Samjin Pharmaceutical Co., Ltd.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Yu Mi Ji ,  Hee Jong Shin ,  Min Hyo Ki ,  Yong Bin Park ,  Ji Hyun Um

IPC: C07H21/02 ,  A61K9/00 ,  A61K9/08 ,  A61K47/22 ,  A61P35/02

CPC classification number: C07H21/02 ,  A61K9/0019 ,  A61K9/08 ,  A61K47/22 ,  A61P35/02

Abstract: Disclosed is an oligonucleotide-modified nucleic acid containing at least one 1-β-D-arabinofuranosylcytosine as a modified nucleic acid having therapeutic efficacies and guanosine. More particularly, a novel oligonucleotide-modified nucleic acid containing at least one modified nucleic acid (N) having therapeutic efficacies and being rich in guanosine (G) is synthesized and the fact that the novel oligonucleotide-modified nucleic acid has excellent apoptotic activities on blood cancer cells and drug-resistant blood cancer cells is identified. Based on this, provided is a composition for preventing, ameliorating or treating blood cancer, containing the novel oligonucleotide-modified nucleic acid, and the novel oligonucleotide-modified nucleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

公开(公告)号：US20230067461A1

公开(公告)日：2023-03-02

申请号：US17791983

申请日：2021-01-12

Applicant: Aptabio Therapeutics Inc.

Inventor： Soo Jin LEE ,  Sung Hwan MOON ,  Soo Ho BAN ,  Eun Sil LEE ,  Eun Jung SHIN ,  Yoo-Kyung GOH ,  Sung Chan LEE ,  Hyun Kyung KU

IPC: C07D401/04 ,  C07D471/04 ,  C07D519/00

Abstract: The present invention provides a novel pyrazole derivative compound represented by Chemical formula I or a salt thereof, and a pharmaceutical composition comprising the same.

公开(公告)号：US10966969B2

公开(公告)日：2021-04-06

申请号：US16481307

申请日：2018-09-14

Applicant: APTABIO THERAPEUTICS INC.

Inventor： Sung Hwan Moon ,  Soo Jin Lee ,  Sung Chan Lee ,  Yun Soo Bae

IPC: A61K31/4439 ,  A61P1/16

Abstract: Disclosed is a pharmaceutical composition for preventing or treating a fatty liver disease containing, as an active ingredient, a pyrazole-based compound or a pharmaceutically acceptable salt thereof. 3-phenyl-4-alkyl-1-(pyridin-2-yl)-1H-pyrazol-5-ol or a pharmaceutically acceptable salt thereof is capable of effectively inhibiting fatty liver, hepatic inflammation and hepatic fibrosis, and is useful for preventing or treating NAFLD, in particular, NASH.

公开(公告)号：US20120202981A1

公开(公告)日：2012-08-09

申请号：US13381326

申请日：2010-06-29

Applicant: Soo Jin Lee ,  Sung Hwan Moon

Inventor： Soo Jin Lee ,  Sung Hwan Moon

IPC: C07H21/00

CPC classification number: C07H19/173 ,  C07H21/00

Abstract: The present invention relates to a novel modified oligonucleotide comprising at least one guanosine molecule and a modified nucleic acid with therapeutic efficacies. The present invention also relates to a pharmaceutical composition having cell apoptotic activity against cancer cells for preventing or treating cancer comprising a guanosine-rich modified oligonucleotide with at least one therapeutically effective modified nucleic acid (N), or its pharmaceutically acceptable salt as active ingredient.

Abstract translation: 本发明涉及包含至少一种鸟苷分子和具有治疗功效的修饰的核酸的新型修饰寡核苷酸。 本发明还涉及具有细胞凋亡活性的药物组合物，其具有用于预防或治疗癌症的细胞凋亡活性，其包含富含鸟嘌呤的修饰的寡核苷酸与至少一种治疗有效的修饰的核酸（N）或其药学上可接受的盐作为活性成分。